### REPORT DOCUMENTATION PAGE

Form Approved OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

| 1. AGENCY USE ONLY (Leave black       | ink) | 2. REPORT DA                 | (TE  | 3. REPORT TYPE AN                    | 3. REPORT TYPE AND DATES COVERED |                            |  |
|---------------------------------------|------|------------------------------|--|--------------------------------------|----------------------------------|----------------------------|--|
|                                       |      | 21.S                         | Sep.05   | •                                    | TH                               | ESIS                       |  |
| 4. TITLE AND SUBTITLE                 |      |                              | <del>,                                    </del> |                                      |                                  | ING NUMBERS                |  |
| AMPLIFICATION OF HERPES               |      |                              |  |                                      |                                  |                            |  |
| HERPES VIRUS TYPE 5 POLY              |      |                              |  |                                      |                                  |                            |  |
| FORMALIN-FIXED BRAIN TIS              | SSUE | 3 FROM ALZ                   | HEIMER'S   | DISEASE                              |                                  |                            |  |
| CAPT HENRICHS LORI E                  |      |                              |  |                                      |                                  |                            |  |
| <b></b>                               |      |                              |  |                                      | }                                |                            |  |
|                                       |      | •                            |  |                                      |                                  |                            |  |
| 7. PERFORMING ORGANIZATION            |      |                              | RESS(ES)   |                                      |                                  | ORMING ORGANIZATION        |  |
| UNIVERSITY OF TEXAS AT S              | SAN. | ANTONIO                      |  |                                      | REPO                             | RT NUMBER                  |  |
|                                       |      |                              |  |                                      |                                  | CI04-1261                  |  |
|                                       |      |                              |  |                                      |                                  | C107-1201                  |  |
|                                       |      |                              |  |                                      |                                  |                            |  |
| 9. SPONSORING/MONITORING A            | GENC | Y NAME(S) AN                 | ND ADDRESS                                       | (ES)                                 | 10. SPOI                         | NSORING/MONITORING         |  |
| THE DEPARTMENT OF THE                 |      |                              |  | 120,                                 |                                  | NCY REPORT NUMBER          |  |
| AFIT/CIA, BLDG 125                    |      |                              |  | *                                    |                                  | ,                          |  |
| 2950 P STREET                         |      |                              |  |                                      |                                  |                            |  |
| WPAFB OH 45433                        |      |                              | ·  |                                      |                                  |                            |  |
| 11. SUPPLEMENTARY NOTES               |      |                              |  |                                      |                                  |                            |  |
| 11. SUPPLEIVIENTANT NOTES             |      | •                            |  |                                      |                                  |                            |  |
|                                       |      |                              |  |                                      |                                  |                            |  |
|                                       |      |                              |  | •                                    |                                  |                            |  |
| 12a. DISTRIBUTION AVAILABILITY        | STAT | EMENT                        |  |                                      | 12b. DIS                         | TRIBUTION CODE             |  |
| Unlimited distribution                |      |                              |  |                                      |                                  | ·                          |  |
| In Accordance With AFI 35-205         | /AFI | Γ Sup 1                      | *  |                                      |                                  | ·                          |  |
|                                       |      |                              |  |                                      |                                  |                            |  |
|                                       |      |                              |  | •                                    |                                  | ,                          |  |
| 13. ABSTRACT (Maximum 200 wor         | rds) |                              |  |                                      | l                                |                            |  |
| -                                     |      |                              |  |                                      |                                  |                            |  |
|                                       |      | ,                            |  |                                      |                                  |                            |  |
|                                       |      |                              |  |                                      |                                  |                            |  |
|                                       |      |                              |  |                                      |                                  |                            |  |
|                                       |      |                              |  |                                      |                                  | !                          |  |
|                                       |      |                              |  |                                      |                                  | •                          |  |
|                                       |      |                              |  |                                      |                                  | •                          |  |
|                                       |      |                              |  |                                      |                                  |                            |  |
|                                       |      |                              |  |                                      |                                  |                            |  |
|                                       |      |                              | •  | DISTRIBU                             | TION S                           | STATEMENT A                |  |
|                                       |      |                              | •  | Approved                             | d for Pu                         | ıblic Releas <b>e</b>      |  |
|                                       |      | •                            |  |                                      |                                  | Unlimited                  |  |
| ·                                     |      |                              |  |                                      | •                                |                            |  |
|                                       |      |                              |  |                                      | 4                                |                            |  |
| 14. SUBJECT TERMS                     |      | <u></u>                      |  |                                      |                                  | 15. NUMBER OF PAGES        |  |
|                                       |      |                              |  |                                      | •                                | 27                         |  |
| ·                                     |      |                              | •  | •                                    |                                  | 16. PRICE CODE             |  |
|                                       |      |                              |  |                                      |                                  |                            |  |
| 17. SECURITY CLASSIFICATION OF REPORT |      | ECURITY CLASS<br>F THIS PAGE | SIFICATION                                       | 19. SECURITY CLASSIFI<br>OF ABSTRACT | CATION                           | 20. LIMITATION OF ABSTRACT |  |
|                                       |      |                              |  | or notification                      |                                  |                            |  |
| <u>i</u>                              |      |                              |  |                                      |                                  | !                          |  |

# AMPLIFICATION OF HERPES SIMPLEX VIRUS TYPES 1 AND 2 AND HUMAN HERPES VIRUS TYPE 5 POLYMERASE GENE SEGMENT FROM FORMALIN-FIXED BRAIN TISSUE FROM ALZHEIMER'S DISEASE PATIENTS

by

LORI ELLEN HENRICHS, B.S.

### **THESIS**

Presented to the Graduate Faculty of
The University of Texas at San Antonio
in Partial Fulfillment
of the Requirements
for the Degree of

MASTER OF SCIENCE IN BIOLOGY

THE UNIVERSITY OF TEXAS AT SAN ANTONIO
College of Sciences
Department of Biology
August 2005

20050929 045

THE VIEWS EXPRESSED IN THIS ARTICLE ARE THOSE OF THE AUTHOR AND DO NOT REFLECT THE OFFICIAL POLICY OR POSITION OF THE UNITED STATES AIR FORCE, DEPARTMENT OF DEFENSE, OR THE U.S. GOVERNMENT.

### **ACKNOWLEDGEMENTS**

I would like to express my gratitude to Dr. James P. Chambers, my thesis advisor, for his supervision of my work. I would like to thank Dr. Tao Wei and Dr. G. Jilani Chaudry for serving on my examination committee. I am thankful to Luke Daum for his help on sequencing and other protocols. Finally, I extend my deepest thanks to my colleagues, friends and classmates John Rodriguez, Charuta Ambardekar and Richard Tamfu for all their support and cooperation during my course of work in Dr. Chambers' laboratory.

# AMPLIFICATION OF HERPES SIMPLEX VIRUS TYPES 1 AND 2 AND HUMAN HERPES VIRUS TYPE 5 POLYMERASE GENE SEGMENT FROM FORMALIN-FIXED BRAIN TISSUE FROM ALZHEIMER'S DISEASE PATIENTS

APPROVED BY SUPERVISING COMMITTEE:

Dr. James P. Chambers, Chair

Dr. Tao Wei

Dr. G. Jilàni Chaudry

David Senseman, Graduate Advisor

Accented:

Dean of Graduate School

# AMPLIFICATION OF HERPES SIMPLEX VIRUS TYPES 1 AND 2 AND HUMAN HERPES VIRUS TYPE 5 POLYMERASE GENE SEGMENT FROM FORMALIN-FIXED BRAIN TISSUE FROM ALZHEIMER'S DISEASE PATIENTS

Lori Ellen Henrichs, M.S. The University of Texas at San Antonio, 2005

Supervising Professor: James P. Chambers

It is known that nucleic acids from formalin-fixed tissues are not nearly as good templates for DNA amplification as those extracted from fresh tissue. However, specimens stored in most pathologic archives are initially fixed in formalin. The possibility of an infectious etiology of several diseases, including Alzheimer's disease (AD), underscores the usefulness of archived tissue in assessing the association of infectious agents with specific pathology. Previous studies have used frozen brain tissue samples and cerebrospinal fluid (CSF) specimens to determine whether Herpes simplex virus type 1 (HSV1) is present more frequently in Alzheimer's disease brain tissue than in the brains of elderly normal subjects. The DNA extraction method used in this study resulted in extraction of DNA from formalin-fixed brain tissue samples. The neuronal nitric oxide synthase (NOS1) gene target was amplified and sequenced in all samples tested, in addition to HSV1, HSV2, or Human Herpes virus type 5 (HHV5) from respective samples.

iv

# TABLE OF CONTENTS

| Acknowledgements                     | iii |
|--------------------------------------|-----|
| Abstract                             | iv  |
| List of Figures                      | vi  |
| List of Tables                       | vi  |
| List of Abbreviations                | vii |
| Introduction                         | 1   |
| Materials                            | 5   |
| Methods                              | 6   |
| A. Formalin Removal                  | 6   |
| B. DNA Extraction                    | 7   |
| C. PCR                               | 8   |
| D. Reamplification of PCR Product    | 9   |
| E. Purification of Amplified Product | 10  |
| F. Sequencing                        | 10  |
| Results                              | 12  |
| Discussion                           | 16  |
| References                           | 18  |
| Vita                                 |     |

# LIST OF FIGURES

| Fig 1: Agarose Gel Electrophoresis of NOS1 Gene Target                     | 13 |
|--|----|
| Fig 2: Agarose Gel Electrophoresis of Herpes Virus Polymerase Gene Targets | 13 |
| Fig 3: NOS1 Gene Target Sequence.  | 14 |
| Fig 4: Sequence of HSV1, HSV2, and HHV5 Polymerase Gene Targets            | 14 |
|  |    |
| LIST OF TABLES   |    |
| Table 1: Herpes Virus Positive Sequence Results                            | 15 |
| Table 2: Percent Samples Testing Positive for Herpes Virus by Type         | 15 |

## LIST OF ABBREVIATIONS

AD Alzheimer's disease

ApoE Apolipoprotein E

bp Base Pair

CSF Cerebrospinal Fluid

CMV Cytomegalovirus

ddNTP Dideoxy Nucleotide Triphosphate

DNA Deoxyribonucleic acid

GAPDH Glyceraldehyde-3-phosphate dehydrogenase

HSV Herpes Simplex Virus

HSV1 Herpes Simplex Virus Type 1

HSV2 Herpes Simplex Virus Type 2

HHV5 Human Herpes Virus Type 5

HHV6 Human Herpes Virus Type 6

NOS1 Neuronal Nitric Oxide Synthase

PBS Phosphate Buffered Saline

PE Phosphate Ethanol

PCR Polymerase Chain Reaction

### INTRODUCTION

Alzheimer's disease (AD) is an age-related, irreversible neurodegenerative disorder. AD results in memory loss and a decline in cognitive function which ultimately leads to a total degradation of intellectual and mental capabilities. AD is the leading cause of dementia with 20 million reported cases worldwide. Afflicting 1 in 5 people over the age of 80, AD is responsible for the deaths of one half million Americans each year (1). Although not the cause of AD, current studies suggest that HSV1 infection of the brain is a significant risk factor. HSV1 infection potentially predisposes individuals to increased inflammation, neuritic plaque and neurofibrillary tangle formation, and beta-amyloid deposition.

The Herpes simplex viruses (HSV) belong to the alpha herpesvirus subfamily of herpesviruses. These enveloped viruses possess a double stranded DNA genome approximately 150 kb in size. The genome of Herpes simplex virus type 1 (HSV1) and Herpes simplex virus type 2 (HSV2) share 50-70 % homology. HSV1 is primarily associated with oral and ocular lesions, while HSV2 is primarily associated with genital and anal lesions. During the primary infection stage, the virus enters peripheral sensory nerves and migrates along axons to sensory nerve ganglia in the CNS allowing the virus to escape the immune surveillance system. Reactivation of latent virus in nerve cells leads to recurrent disease. The virus travels back down sensory axons where it establishes an infection in the epithelium of the skin and replicates.

Human Herpes virus type 5 (HHV5), also known as Cytomegalovirus (CMV), belongs to the beta herpesvirus subfamily of herpesviruses and like the alpha subfamily members is enveloped, possessing a slightly larger double stranded DNA genome of approximately 230 kb. HHV5 infection is common and most infections are asymptomatic. Apart from during pregnancy and newborn infants exposed *in utero*, active HHV5 infection only occurs in individuals with

immune defects such as AIDS and immunosuppressed organ transplant patients. Transmission is believed to be by oral/respiratory route.

HSV1 has been proposed as a possible factor in Alzheimer's disease based on the following: several neurological disorders are caused by common viruses; HSV1 is ubiquitous with predilection for latent residence in the peripheral nervous system; and in acute HSV1 encephalitits, the virus targets the same regions of the central nervous system (temporal and frontal cortex, and hippocampus) as those most affected in AD (2).

It has been established using the polymerase chain reaction (PCR) that HSV1 is present in a high proportion of brains of elderly normal subjects and AD patients (3). In younger individuals, the virus is almost always absent in brain. It was therefore suggested that HSV1 reaches the brain in older age as the immune system declines and resides there in latent form. Under conditions of stress or immunosuppression, HSV1 reactivates and gives rise to an acute but localized infection, the damage being more serious in people who possess an APOE-e4 allele (4).

Under appropriate circumstances, the other human herpesviruses can all be neuroinvasive and could therefore act as another possible risk factor for AD. Although rare, HSV2 can also give rise to brain stem encephalitis and has been shown to be the cause of a progressive dementia syndrome diagnosed as AD based on clinical criteria (3). The nervous system is one of the main targets in CMV congenital infection. Mental retardation is common-place in survivors of congenital CMV infection. The virus can also cause encephalitis; although, it is rare in immunocompetent people (3).

Neuronal nitric oxide synthase (NOS1) gene is a universal mediator of biological effects in the brain. NOS1 is involved in many biological systems; neurotransmission, the regulation of body fluid homeostasis, neuroendocrine physiology, control of some muscle, motility, sexual function, and myocyte/myoblast biology (5). In all experiments preformed using formalin-fixed brain tissue described in this study, the NOS1 gene was consistently amplified. Thus, NOS1 proved to be a better internal control standard than that of the housekeeping gene, glyceralde-3-phosphate dehydrogenase (GAPDH). Thus, the NOS1 gene was used as an internal control to verify successful removal of formalin that inhibits PCR amplification of DNA. The NOS1 gene is located on human chromosome 12 and spans nearly 150 kb. The gene is comprised of 29 exons and 28 introns. The nucleotide sequence located on exon 19 was used in assigning forward and reverse primers giving rise to 251 bp amplicon.

The focus of this thesis is examination of formalin-fixed, post-mortem brain tissue from patients with Alzheimer's disease for the presence of HSV1, HSV2, and HHV5 DNA using PCR. A number of studies have been completed over the past 20 years to assess whether the presence of HSV1 in aged brain is associated with AD using frozen post-mortem brain tissue sections and cerebrospinal fluid (CSF) specimens. However, little research has been conducted determining the presence of viral DNA in formalin-fixed brain tissue.

Although 10 % formalin (3.7 % formaldehyde) treatment of tissue is associated with deleterious interactions of varying degree with DNA (6-11), formalin provides the most adequate means of tissue preservation insuring optimal features of histological purposes (11).

In 1990, Nicoll, et al. detected viral DNA using formalin-fixed, paraffin-embedded brain samples from patients with acute HSV1 encephalitis by PCR (13). Bertrand and coworkers subsequently described PCR based detection of HSV1 viral DNA in specific formalin-fixed brain tissue regions of Alzheimer patients (14). Recently, Hemling and coworkers detected HSV1, Human Herpes virus type 6 (HHV6) and varicella zoster viral DNA using PCR in human brain, but the source of PCR template DNA is unclear (14). However, using the methods of Nicoll

(13), Bertrand (14), and Hemling (15), we were not successful in detecting by PCR the key glycolytic enzyme (GAPDH) commonly used as a marker to exclude false negative results.

Assay variation could arise from differences in inherent molecular profiles; however, such intrinsic tissue factors affecting PCR amplification of template DNA in archived tissue are not easily identified.

In this study, the presence of HSV1, HSV2 and HHV5 was detected in formalin-fixed brain tissue sections from patients with AD using PCR. This study demonstrated the utility of post-analysis nucleic acid extraction developed in this laboratory and PCR amplification using formalin-fixed tissue. Considering the large number of archived tissue samples available, the procedure employed in this study could be used in assessing the association of infectious agents with specific pathology in archived brain tissue.

### **MATERIALS**

Proteinase K, Cell Lysis Solution and MPC Protein Precipitation Reagent were obtained from Epicentre Biotechnologies, Madison, Wisconsin. Xylene, 100 % Ethanol and 99 % (v/v) Isopropanol were obtained from Sigma-Aldrich Co., St. Louis, Missouri. Nuclease Free double distilled water was obtained from Ambion Inc., Austin, Texas. HSV1 and HSV2 viral cultures from Cell Lines A549 and MRC5 were obtained from Brooks City Base, San Antonio, Texas. HHV5 has obtained from American Type Culture Collection, Manassas, Virginia. The universal primer set specific for the polymerase HSV1, HSV2, and HHV5 gene sequences and primer set specific for the NOS1 gene target were obtained from Integrated DNA Technologies, Inc., Coralville, Iowa. Reaction Mix 2X from the 'Superscript II One Step-RT-PCR', Platinum Taq DNA Polymerase and 2 % (w/v) E-Gel<sup>R</sup> Agarose gels were obtained from Invitrogen Corporation, Carlsbad, California. Molecular weight ladder (100 bp) were obtained from Bio-Rad Laboratories Inc., Hercules, California. Human Genomic DNA was obtained from Roche Diagnostics GmbH, Penzberg, Germany. Ultracentrifuge-MC centrifugal filter devices were obtained from Amicon Corporation, Billerica, Massachusetts. QIAquick PCR Purification Kit and DyeEx<sup>TM</sup> 2.0 Spin Kit were obtained from Qiagen Inc., Valencia, California. Big Dye Terminator v3.1 Cycle Sequencing RR-100 and Formamide were obtained from Applied Biosystems, Foster City, California. Feather Sterile Surgical Blade and Fisherbrand 2 mL and 1.5 mL microcentrifuge tubes were obtained from Fisher Scientific International Inc., Houston, Texas. Formalin-fixed Alzheimer patient brain tissue was obtained from the Honolulu Heart Program, Honolulu, Hawaii.

### **METHODS**

The extraction and amplification of DNA from formalin-fixed brain tissue used in this study is a multi-step process and is summarized below.

Step 1: Tissue preparation

Step 2: Xylene extraction (formalin removal)

Step 3: Cell lysis/protein digestion

Step 4: PCR amplification

Step 5: Agarose gel electrophoresis of amplicons

Step 6: Amplicon cleanup

Step 7: Sequencing

### A. Formalin Removal

Formalin-fixation reduces significantly the success of PCR amplification primarily because of modification and cross-linking of DNA. Although not firmly established, it appears that xylene treatment in addition to removing formalin also removes residual inhibitors derived from formalin-fixation. Approximately 10-15 mg of tissue was processed by mincing the tissue using a sterile surgical blade. Once completed, the finely minced tissue was transferred to a 2 mL microcentrifuge tube and to each sample 1 mL xylene was added. The contents were then vortexed vigorously for 5 seconds, followed by incubation at room temperature for 15 minutes. Xylene was decanted and discarded using a pipette. This step was repeated twice. Residual xylene removal was accomplished by addition of 1 mL ACS grade, 100 % ethanol, vortexed for 5 seconds, and incubated at room temperature for 5 minutes. This procedure was repeated once. Samples were desiccated for at least 30 minutes in order to thoroughly dry the pellets removing residual xylene which inhibits subsequent Proteinase K digestion.

### B. DNA Extraction

Successful DNA extraction requires that cells be lysed making the DNA assessable for subsequent steps. Proteinase K enzymatically degrades protein which aids lysis, freeing up DNA from associated protein. Nucleic acids are precipitated by addition of isopropyl alcohol to the supernatant material following centrifugation of the Proteinase K digest mixture. DNA extraction was accomplished using modification of the Epicentre MasterPure reagent DNA extraction procedure (16). Tissue and Cell Lysis Solution (300 ul) containing 2 ul 50 mg/ml Proteinase K and 10 ul 50 ug/ul Proteinase K in a total volume of 312 ul was added to each sample. The reaction mixture containing the tissue sample and Proteinase K cocktail was mixed thoroughly and incubated at 65° C overnight. Following incubation, samples were placed on ice for 4 minutes. To the lysed sample, 150 ul MPC Protein Precipitation Reagent was added, gently agitated for 10 seconds and resulting debris removed by centrifugation for 10 minutes at 9,000 x g using a microcentrifuge. Supernatant material was carefully decanted and transferred to a 2 mL microcentrifuge tube. Isopropyl alcohol (500 ul) (99 % (v/v) molecular biology grade) was added to the supernatant and each sample was inverted multiple times (~50). DNA was pelleted by centrifugation at 5° C for 10 minutes at 9,000 x g. Isopropyl alcohol was carefully aspirated without dislodging the DNA pellet. The pellet material was washed twice with 35 ul 75% (v/v) molecular biology grade ethanol, gently tapping the tube for approximately 8 seconds each wash. Xylene (200 ul) was added to the respective DNA pellets, incubated at room temperature for 15 minutes followed by bulk removal of xylene using a pipette. Residual xylene was removed by adding to each sample 500 ul 100 % ethanol, followed by incubation at room temperature for 5 minutes. Samples were desiccated for 30 minutes in order to remove residual

ethanol followed by resuspension in 20 ul nuclease free water. This material served as DNA template for PCR amplification.

### C. PCR

PCR amplifies the desired targeted DNA sequence giving rise to large amounts of amplified product (amplicons). Control DNA obtained from HSV1, HSV2, and HHV5 cultures and tissue extracted DNA was quantitated spectrophotometrically. Tenfold dilutions ranging from 100 ng/ul to 1 pg/ul were made for each of the templates using nuclease-free water. Detection of HSV1, HSV2 and HHV5 template control DNA was observed in a range of 100 ng/ul to 1 pg/ul under the conditions described below. To each reaction was added 2 ul of each DNA dilution per 20 ul total reaction volume. A universal primer set derived from the HSV1, HSV2 and HHV5 viral polymerase gene sequences produced expected PCR amplicon products of 235 (HSV1 and HSV2) and 238 (HHV5) base pairs using the forward and reverse primer sequences 5'-TCATCTACGGGGACACGGAC-3' and 5'-TTGCGCACCAGATCCACG-3', respectively. The nucleotide sequence from the NOS1 gene served as an internal control and was amplified (251 bp product). The NOS1 forward primer sequences used were: 5'-GGCCAACAATTCCC-TCATCAGCAA-3' and reverse 5'-TGAGTGTGGGAGAGCAGCAAAGTA-3', respectively.

PCR reactions (20 ul total volume) for amplification of herpes viral and NOS1 gene targets were carried out using 2X Superscript II one Step-RT-PCR with Platinum Taq system reaction master mix at a final 1X concentration containing 0.5 nM of each primer and 0.1 U/ul Platinum Taq DNA polymerase. Reaction volumes were all brought to 20 ul with nuclease-free water. Conditions for amplification of herpes virus gene targets were as follows: initial denaturation for 3 minutes at 95° C, followed by 35 cycles consisting of DNA melting for 30 seconds at 95° C, primer-annealing for 15 seconds at 54° C, and primer elongation at 68° C for 30 seconds. The

final elongation reaction was carried out for 7 minutes at 68° C. Conditions for amplification of NOS1 gene was as follows: initial denaturation for 2 minutes at 94° C, followed by 35 cycles consisting of DNA melting for 15 seconds at 94° C, primer-annealing at 15 seconds at 52° C and primer elongation at 72° C for 20 seconds. The final elongation reaction was carried out for 5 minutes at 72° C. All PCR reactions were carried out using a Robocylcer 96 Gradient Cycler with hot top (Stratagene, La Jolla, California).

PCR products were separated by electrophoresis using 2 % (w/v) E-Gel agarose gels containing ethidium bromide and visualized under Fisher Biotech UV Transilluminator (Fisher Scientific International Inc., Vernon Hills, Illinois). The respective amplicon products were size characterized using markers of known size. Stained gels were archived using a Fisher Biotech photo-documentation camera (Fisher Scientific International Inc., Vernon Hills, Illinois).

### D. Reamplification of PCR Product

Reamplification of amplicon material was carried out after removing the respective gel areas containing the bands from the gel using a surgical blade. Each gel slice was transferred to an Ultracentrifuge-MC centrifugal filter. The centrifugal filter is designed to extract 100 to 10,000 bp DNA segments from agarose gel slices. The device utilizes gel compression to extract DNA from the agarose. Centrifugal force collapses the gel structure pushing the agarose through the gel nebulizer as a slurry that is captured by the Ultrafree-MC filter. Extruded DNA dissolved in electrophoresis buffer passes through the membrane and collects in the filtrate vial. The Ultracentrifuge-MC centrifugal filter device was centrifuged at 9,000 x g for 10 minutes using an Eppendorf Centrifuge 5417C (Eppendorf AG, Hamburg, Germany). Respective filters were discarded and eluent material used for reamplification. Reamplification was carried out using

2 ul gel slice eluent material under conditions identical to those described above. Reamplification of the product was verified by agarose gel electrophoresis as previously described.

### E. Purification of Amplified Product

Amplified products were cleaned up using the manufacturer's protocol for the QIAquick PCR Purification Kit. The protocol is designed to purify single or double stranded DNA fragments from PCR reactions. Amplicons ranging from 10 to 100 kb are purified away from primers, nucleotides, polymerases and salts using the QIAquick spin columns in a microcentrifuge. DNA i.e., amplicons, adsorb to the silica-membrane in the presence of high salt while contaminants pass through the column. After the impurities are washed away, the pure DNA is eluted from the silica-membrane with Tris buffer.

All centrifugation steps were carried out at 15,600 x g in an Eppendorf 5417C tabletop centrifuge. Five volumes of PBS were added to one volume of sample and mixed well. The sample was applied to a QIAquick spin column collection tube and centrifuged for 60 seconds. Flow-through was discarded. PE buffer (750 ul) was added to the column and centrifuged for 60 seconds. Flow-through material was discarded and bound DNA was eluted by adding 30 ul elution buffer (allowed to stand for 1 minute), followed by centrifugation for 60 seconds.

### F. Sequencing

Sequencing was carried out to validate the amplicons produced following amplification.

Sequencing is based on the same principle as that of the Sanger DNA method of sequencing.

The ddNTP's are fluorescently labeled with different dyes and act as chain terminators. The four dyes fluoresce at different wavelengths. A laser determines the identity of each according to the wavelength at which it fluoresces. Results are expressed in the form of a chromatogram i.e., a

diagram of colored peaks corresponding specifically to the nucleotide in that location in the sequence.

Typical sequencing reactions consisted of 4 ul Big Dye Terminator v3.1 Cycle sequencing RR-100, 5 ul nuclease free water, and 1 ul 20 uM primer and 10 ul template. Cycle conditions were 95° C for 2 minutes, followed by 35 cycles of 96° C for 5 seconds, 50° C for 5 seconds and 60° C for 4 minutes.

Excess dye terminators were removed using a DyeEx<sup>TM</sup> 2.0 Spin Kit per manufacturer's instructions. The DyeEx procedure is based on separation properties of gel-filtration chromatography. When sequencing reaction contents are applied onto DyeEx modules, dye terminators diffuse into the pores and are retained in the gel-filtration material while the DNA fragments are excluded and recovered in the flow-through. All centrifugation steps were carried out in an Eppendorf Centrifuge 5417C at 700 x g. The spin column was gently vortexed to resuspend the resin. The cap of the tube was loosened a quarter turn. The bottom closure of the spin column was snapped off and the column placed in a 2 mL collection tube. The column was centrifuged for 3 minutes at the calculated speed and transferred to a 1.5 mL centrifuge tube. A 10 ul sequencing reaction aliquot was then applied to the gel bed. The column was centrifuged for 3 minutes at the calculated speed. Respective spin column eluates were dehydrated using a vacuum centrifuge followed by resuspension in 10 ul formamide and samples were subsequently sequenced using an ABI-3100 automated sequencer. (Applied Biosystems, Foster City, California).

### **RESULTS**

Brain tissue from 57 elderly subjects clinically diagnosed with AD were investigated for HSV1, HSV2 and HHV5 polymerase gene targets using PCR. The integrity of the DNA samples used in this study were confirmed by demonstration of amplification of the NOS1 gene following DNA extraction from formalin-fixed tissue samples. A representative gel electrophoretic analysis of NOS1 gene (251 bp) PCR product, i.e., amplicons from formalin-fixed human brain samples positive for the presence of herpes viral DNA is shown in Figure 1. Human genomic DNA was used as a positive control. Reaction mixture without template served as the negative control (no-DNA).

A representative electrophoretic analysis of amplicons produced by amplification of HSV1 and HSV2 (235 bp) and HHV5 viral polymerase (238 bp) gene targets from formalin-fixed human brain is shown in Figure 2. Viral control DNA obtained from HSV1, HSV2, and HHV5 viral cultures was used for size comparison of amplicons.

Reamplification of respective gel slice extracted bands and subsequent sequence analysis confirmed the identity of the amplicons. All nucleotide sequences were subjected to a PubMed BLAST search and all sequences correlated to known HSV sequences shown in Figures 3 and 4. As shown in Tables 1 and 2, 11 of the 57 AD samples were found to be positive for herpes virus sequences (3 HSV1, 5 HSV2 and 3 HHV5).

Figure 1. Agarose Gel Electrophoresis of NOS1 Gene Target.

Electrophoretic analysis of NOS1 gene amplicon (251 bp) from formalin-fixed brain tissue samples was carried out as previously described. Lane 1, 100-bp molecular weight ladder. Lane 2, GAPDH control. Lanes 2-10, HSV positive samples. Lanes 11 and 12, negative (no template) controls.




Figure 2. Agarose Gel Electrophoresis of Herpes Virus Polymerase Gene Targets.

Electrophoretic analysis of Herpes simplex type 1 and 2 (235 bp) and Human Herpes type 5 (238 bp) amplicons from formalin-fixed brain tissue samples was carried out as previously described. Lane 1, 100-bp molecular weight ladder. Lane 2, HSV1 (235 bp) positive control. Lane 3, HSV2 (235 bp) positive control. Lane 4, HHV5 (238 bp) positive control. Lanes 5-10, Viral polymerase gene target amplicons from formalin-fixed tissue samples. Lanes 11 and 12, negative (no template) controls.



**Figure 3.** NOS1 Gene Target Sequence. The primers (underlined) give rise to a 251 bp amplicon.

5'GGCCAACAATTCCCTCATCAGCAATGATCGCAGCTGGAAGAGAAACAAGTTCCGC CTCACCTTTGTGGCCGAAGCTCCAGAACTCACACAAGGTACCTCCCACCACCACCTTCC AGGGAGGTATTCGTGACAATGGGGGAAAGGCAGGTGATCTCACCTCCAGAAGGTGC TTAGAGAAGATGGGCTTCATTGCTTTGATCTCCCTTTAGTGCAGTCCTACCAAAATG AATACTTTGCTGCTCCCCACACTCA3'

**Figure 4.** Sequence of HSV1, HSV2, and HHV5 Polymerase Gene Target Amplicons. The same set of universal primers was used for all three viruses. The primers (underlined) give rise to a 235 bp amplicon for HSV1 and HSV2, and a 238 bp amplicon for HHV5.

### **HSV1:**

### HSV2:

### **HHV5:**

5'TCATCTACGGGGACACGGACAGCGTGTTTGTCCGCTTTCGTGGCCTGACGCCGCAG GCTCTGGTGGCGCGTGGGCCCAGCCTGGCGCACTACGTGACGGCCTGTCTTTTTGTG GAGCCCGTCAAGCTGGAGTTTGAAAAGGTCTTCGTCTCTCTTATGATGATCTGCAAG AAACGTTACATCGGCAAAGTGGAGGGCGCCCTCGGGTCTGAGCATGAAGGG<u>CGTGGA</u> TCTGGTGCGCAA3'

| NOS1<br>Gene    | HSV PCR  | Herpes Type  |
|-----------------|--|--|
| Positive        | Positive   | HSV1   |
| Positive        | <b>Positive</b>  | HSV1   |
| <b>Positive</b> | <b>Positive</b>  | HSV1   |
| Positive        | <b>Positive</b>  | HSV2   |
| Positive        | <b>Positive</b>  | HSV2   |
| Positive        | Positive   | HSV2   |
| <b>Positive</b> | <b>Positive</b>  | HSV2   |
| <b>Positive</b> | <b>Positive</b>  | HSV2   |
| Positive        | Positive   | HHV5   |
| <b>Positive</b> | Positive   | HHV5   |
| Positive        | Positive   | HHV5   |
|                 | Positive | Positive |

Table1: Herpes Virus Positive Sequence Results.

| Herpesvirus | Results         | Number of<br>Samples | % of Total<br>Samples |
|-------------|-----------------|----------------------|-----------------------|
| HSV1        | Positive        | 3                    | 5.3                   |
|             | Negative        | 54                   | 94.7                  |
| HSV2        | Positive        | 5                    | 8.8                   |
|             | Negative        | 52                   | 91.2                  |
| HHV5        | Positive        | 3                    | 5.3                   |
|             | <b>Negative</b> | 54                   | 94.7                  |

Table 2: Percent Samples Testing Positive for Herpes Virus by Type.

### **DISCUSSION**

HSV1 has been suggested as a factor in AD due to its ubiquitous and neurotropic nature, affecting similar sites as those in AD. A number of studies have been performed on frozen brain tissue sections and CSF in order to assess whether the presence of HSV1 in aged brain is associated with AD. Little research has been carried out in determining the presence of viral DNA in formalin-fixed tissue.

It is known that formalin fixation affects significantly in negative fashion, PCR amplification of gene targets in archived tissue. The DNA extraction method employed in this study resulted in the successful extraction of HSV1, HSV2, and HHV5 DNA residing in formalin-fixed, brain tissue from patients with Alzheimer's disease. The herpes virus template was detectable down to a level of 1 pg/ul. However, virus was not detected in all samples tested. It is possible that the 'multiple stage' nature of AD may affect detection of the virus in tissue samples. It is also possible that the virus might be present in very small, localized regions making detection more difficult (17).

Interestingly, NOS1 was detected, i.e. PCR amplified from all formalin-fixed brain tissue samples in this study. Importantly, the size of the NOS1 amplicon (251 bp) is comparable in size to that of the herpes virus (HSV1 and HSV2, 235 bp and HHV5, 238 bp) amplicons. Thus, the NOS1 proved to be a better internal control than that of the commonly used housekeeping gene, GAPDH for DNA extraction from formalin-fixed brain tissue. In contrast to GAPDH, increased time of storage in formalin did not have an effect on the amplification of NOS1. GAPDH template integrity dramatically decreases with increasing time of storage in formalin suggesting that for some yet to be defined reason, GAPDH is a poor control target in formalin-fixed archived brain. One possible explanation is that the primers used for GAPDH amplification may

be targeting a variable region of the GAPDH gene. Furthermore, it is possible that GAPDH exons are more sensitive to formalin than those coding for NOS1.

This study demonstrates the utility of this method of extraction of DNA from formalin-fixed tissue. Furthermore, the NOS1 gene appears to be a superior control candidate target in archived brain. Considering the large quantity of archived brain available, the findings described here could be useful in assessing the association of infectious agents with specific pathology in archived brain tissue.

### **REFERENCES**

- 1. Hill, J.M., Gebhardt, B.M., Azcury, A.M., Matthews, K.E., Lukiw, W.J., Steiner, I., Thompson, H.W., and Ball, M.J. (2005) Can a herpes simplex virus type 1 neuroinvasive score be correlated to other risk factors in Alzheimer's disease? *Medical Hypotheses* 64, 320-327.
- 2. Itzhaki, R.F., Lin, W., Shang, D., Wilcock, G.K., Faragher, B. and Jamieson, G. (1997) Herpes simplex virus type 1 in brain and risk of Alzheimer's disease. *The Lancet* 349, 241-244.
- 3. Lin, W., Wozniak, M.A., Cooper, R.J., Wilcock, G.K., and Itzhaki, R.F. (2002) Herpes viruses in brain and Alzheimer's disease. *Journal of Pathology* 197, 395-402.
- 4. Itzhaki R.F., Wozniak, M.A., Appelt, D.M., Balin, B.J. (2004) Infiltration of the brain by pathogens causes Alzheimer's disease. *Neurobiology of Aging* 25, 619-627.
- 5. Hall, A.V., Yang Wang, H.A., Cheung, A.H., Arbus, A.M., Olson, S.L., Lu, W.C., Kau, C. and Marsdens, P.A. (1994) Structural Organization of the Human Neuronal Nitric Oxide Synthase Gene (NOS 1). *The Journal of Biological Chemistry* 269, 33082-33090.
- 6. Fraenkel-Conrat, H. (1954) Reaction of nuclei acid with formaldehyde. *Biochem. Biophys. Acta* 15, 307-309.
- 7. Staehelin, M. (1958) Reaction of tabacco mosaic virus nucleic acid with formaldehyde. *Biochem. Biophys. Acta* 29, 410-417.
- 8. Douglas, M.P. and Rogers, S.O. (1998) DNA damage caused by common cytological fixatives. *Mutation Reasearch* 401, 77-88.
- 9. Diaz-Cano S.J. and Brady S.P. (1997) DNA extraction from formalin fixed, paraffin embedded tissues: protein digestion as a limiting step for retrieval of high quality DNA. *Diagn. Mol. Pathol.* 6, 342-346.
- 10. McGhee J.D. and von Hippel, P.H. (1997) Formaldehyde as a probe of DNA structure. Mechanism of the initial reaction of formaldehyde with DNA. *Biochemistry* 16, 3276-3293.
- 11. Williams, C., Ponten, F., Moberg, C., et al. A high frequency of sequence alterations is due to formalin fixation of archival specimens. *Am. J. Pathol.* 155, 1467-1471.
- 12. Paska, C., Bogi, K., Szilak, L., Tokes, A., Szabo, E., Sziller, I., Rigo, J., Sobel., G., Szabo, I., Novak, P., Kiss, A. and Schaff, Z. (2004) Effects of Formalin, Acetone and RNAlater Fixatives on Tissue Preservation and Different Size Amplicons by Real-Time PCR form Paraffin-Embedded Tissue. *Diagn. Mol. Pathol.* 13, 234-240.

- 13. Nicoll, J.A.R., Maitland, N.J. and Love, S. (1991) Use of the polymerase chain reaction to detect herpes simplex virus DNA in paraffin sections of human brain at necropsy. *J. Neurol. Neurosurg. Pyschiatry* 54, 167-168.
- 14. Bertrand, P., Guillaume, D., Hellauer, K., Dea, D., Lindsay, J., Kogan, S., Gautheir, S. and Poirer, J. (1993) Distribution of Herpes Simplex Virus Type 1 DNA in Selected Areas of Normal and Alzheimer's Disease Brains: A PCR Study. *Neurodegeneration* 2, 201-208
- 15. Hemling, N., Roytta, M., Rinne. J., Pollanen, P., Broberg, E., Tapio, V., Vahlberg, T. and Hukkanen, V. (2003) Herpes viruses in Brains in Alzheimer's and Parkinson Diseases. *Ann. Neurol.* 54, 267-271.
- 16. Epicentre. Isolation of DNA from Paraffin-Embedded Tissue Using the MasterPure TM Complete DNA and RNA Purification Kit. <a href="http://www.epicentre.com/f53pa.asp">http://www.epicentre.com/f53pa.asp</a>.
- 17. Dobson, C.B., Wozniak, M.A., Itzhaki R.F. (2003) Do infectious agents play a role in dementia? *Trends in Microbiology* 11, 312-317.

## **VITA**

Lori Ellen Henrichs was born in Sibley, Iowa and After graduating from Sibley High School in 1986, she enlisted in the United States Air Force. In May 1998 she received the degree of Bachelor of Science from William Carey College, Biloxi, Mississippi. She received her commission in the United States Air Force in August, 1999. In August, 2003, she became a graduate student in the Department of Biology at the University of Texas at San Antonio.